Editing List of Antibody Drugs

{| border="1"
|-
! Antibody
! Company *
! Target
! Indication
! Source
! Approval *
|-
| 3F8
| Memorial Sloan-Kettering Merck
| GD2
| Detection and treatmenf of neuroblastoma
| MOUSE; also with 124I or 131I
| Clinical trials
|-
| Abciximab (ReoPro®)
| Centocor B.V. Eli Lilly& Co.
| Platelet glycoprotein GPIIb/IIIa.
| High risk angioplasty
| CHIMERIC Fab fragment
| FDA 1994
|-
| Abagovomab
| Menarini
| Act as surrogate antigen
| Ovarian cancer
| MOUSE anti-idiotype
| Clinical trials
|-
| Adalimumab (Humira ® Trudexa®)
| Abbott Laboratories
| TNFα
| Autoinmune disorders like arthritis reumatoid, psoriasis, Crohn's disease
| HUMAN
| FDA 2002 EMEA 2003
|-
| Adecatumumab (MT201)
| Micromet (MITI)
| EpCAM-CD326
| Tumor cells (prostate, breast cancers)
| HUMAN
| Clinical trials
|-
| Afelimomab(Segard ™)
| BASF, Abbot laboratories
| TNFα
| Sepsis
| MOUSE (Fab')2 fragment
| Failure of clinical trials
|-
| Afutuzumab (Obinutuzumab) (GA-101, RO5072759)
| Hoffmann-La Roche
| CD20
| Lymphoma
| HUMANIZED
| Clinical trials
|-
| Alacizumab pegol (CDP791, gl65 DFM-PEG)
| Celltech, UCB
| VEGFR2
| Non-small cell lung cancer
| HUMANIZED F(ab')2 fragment- pegylated
| Phase II Clinical trials
|-
| ALD518 (BMS-945429)
| Alder Biopharmaceuticals, Inc. / Bristol-Myers Squibb
| IL-6
| Rheumatoid arthritis
| HUMANIZED aglycosylated
| Phase II Clinical trials
|-
| Alemtuzumab (Campath-1H®; MabCampath®)
| Genzyme
| CD52
| Chronic lymphocytic leukaemia; T cell lymphoma
| HUMANIZED
| FDA 2001 EMEA 2001
|-
| Altumomab pentetate (Hybri-CEAker™)
| Hybritech incorporated
| CEA
| Diagnosis of colorectal cancer
| MOUSE- pentetate-l11In
| FDA orphan product 1990
|-
| Anatumomab mafenatox (ABR-214936)
| Active Biotech
| Glycoprotein 5T4
| Non-small cell lung cancer
| MOUSE Fab fragment-superantigen staphylococcal enterotoxin E
| Phase II Clinical trials
|-
| Anrukinzumab (IMA-638)
| Wyeth Pharmaceuticals
| IL-13
| Asthma, colitis ulcerosa
| HUMANIZED
| Clinical trials
|-
| Apolizumab (HulDIO, REMITOGEN™ SMART™)
| PDL (Protein Design Labs) BioPharma
| HLA-DR β
| Non-Hodgkin lymphoma, Chronic lymphocytic leukemia
| HUMANIZED
| Phase II Clinical trials
|-
| Arcitumomab (CEA-Scan®)
| Immunomedics Inc.
| Carcinoembrionic antigen
| Detection of tumors
| MOUSE Ig Fragment- 99mTc
| FDA 1996 EMEA1996 Retired 2005
|-
| Aselizumab
| ?
| CD62L
| Immunosuppressive drug
| HUMANIZED
| Clinical trials
|-
| Atlizumab (Tocilizumab) (Actemra®, RoActemra®)
| Hoffman-la Roche Chugai Pharmaceuticals
| IL-6 receptor
| Rheumatoid arthritis
| HUMANIZED
| EMEA 2009 FDA 2010
|-
| Atorolimumab
| ?
| Rhesus factor
| Immunosuppresive drug
| HUMAN
| ?
|-
| Bapineuzumab
| Wyeth / Elan / Pfizer / J&J
| β amyloid plaques
| Alzheimer's disease/glaucoma
| HUMANIZED
| Clinical trials
|-
| Basiliximab (Simulect ®)
| Novartis Phamaceutical Corp.
| CD25
| Prevent rejection in organ transplantation
| CHIMERIC
| FDA 1998 EMEA 1998
|-
| Bavituximab
| Peregrine Pharmaceuticals, Inc
| Phosphatidylserine
| Cancer, viral infections
| CHIMERIC
| Clinical trials
|-
| Bectumomab (LymphoScan®)
| Immunomedics, Inc
| CD22
| Non-Hodgkin lymphoma
| MOUSE Fab'fragment- 99mTc
| ?
|-
| Belimumab (LymphoStat-B) (Benlysta®)
| Human Genome Sciences GSK
| BAFF (B cell activation factor)
| systemic lupus erythematosus
| HUMAN
| FDA 2011
|-
| Benralizumab (BIW-8405, MEDI-563)
| Medlmmune Inc.
| CD125 (IL-5 receptor)
| Asthma
| HUMANIZED
| Phase II Clinical trials
|-
| Bertilimumab (CAT-213)
| Cambridge Antibody Technology; Ico Therapeutics
| CC111 (Eotaxinl)
| Severe allergic disorders
| HUMAN
| Clinical trials
|-
| Besilesomab (Scintimun®)
| Bayer Schering Pharma A. / CIS bio international
| Carcinoembrionic antigen
| Metastasis and inflammatory lesions
| MOUSE- 99mTc
| EMEA 2009
|-
| Bevacizumab (Avastin®)
| Genentech Inc./ Roche
| VEGF-A
| Cancer, age related macular degeneration
| HUMANIZED
| FDA 2004 EMEA 2005
|-
| Biciromab(l11In) (FibriScint™)
| Centocor
| Fibrin II, β chain
| Thromboembolism diagnosis
| MOUSE Fab'fragment-111In
| Withdrawn during clinical trials
|-
| Bivatuzumab mertansine
| Boehringer Ingelheim
| CD44 v6
| Squamous cell carcinoma
| HUMANIZED-mertansine
| Clinical trials
|-
| Blinatumomab
| Micromet Inc, Medlmmune
| CD19/CD3
| Non-Hodgkin lymphoma, acute lymphoblastic leukemia
| MOUSE
| Orphan drug (EME A/FDA)
|-
| Brentuximab vedotin (SGN-35 and previously cAOO-vcMMAE)
| Seattle Genetics and Millennium
| CD30
| Anaplastic large cell lymphoma; Hodgkin lymphoma
| CHIMERIC (mouse/human)-auristatine
| Clinical trials
|-
| Briakinumab (ABT-874)
| Cambridge Antibody Technology; Abbott Laboratories
| IL-12andIL-23
| Psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
| HUMAN
| Clinical trials Ozespa, withdrawn for EMA
|-
| Canakinumab (Ilaris®)
| Novartis Phamaceutical Corp.
| IL-1β
| Ceryopyrin-associated periodic syndromes
| HUMAN
| FDA 2009 EMEA 2009
|-
| Cantuzumab mertansine (huC242-DMl, SB408075)
| GlaxoSmithKline / ImmunoGen Inc.
| Mucin CanAg
| Colorectal tumor, Pancreatic cancers
| HUMANIZED-mertansine
| Phase I/II Clinical trials
|-
| Capromab Pendetide (111In) (ProstaScint®)
| Cytogen Corp.
| Prostate antigen
| Detection of prostate tumor.
| MOUSE-pentetide-111In
| FDA 1996
|-
| Catumaxomab (Removab®)
| TRION Pharma
| EpCAM and T cells-
| Malignant ascitis with EpCAM-positive carcinomas
| trifuncional antibody
| EMEA 2009
|-
| 125I-CC49
| ?
| TAG-72
| Detection of tumors
| MOUSE-125I
| no tumour response, in Phase I and II trials
|-
| Cedelizumab (ORTHOCLONE OKT4 A)
| Centocor Ortho Biotech Products LP
| CD4
| Prevention of organ transplant rejections and the treatment of autoimmune diseases
| HUMANIZED
| Phase II Clinical trials
|-
| Certolizumab pegol (Cimzia®)
| UCB
| TNFα
| Morbus Crohn, rheumatoid arthritis
| HUMANIZED Fab-pegylated
| FDA 2008
|-
| Cetuximab, C-225 (Erbitux®)
| Imclone Systems/ Bristol-Myers Squibb/ Merck KgaA
| EGFR
| Colorectal, Head and neck cancer
| CHIMERIC
| FDA 2004 EMEA 2004
|-
| ch-TNT
| Shanghai Medipharm Biotech
| DNA associated antigens
| Advanced lung cancer
| CHIMERIC-131I
| China 2003
|-
| Citatuzumab bogatox VB6-845
| 
| TACSTD1
| Ovarian cancer, solid tumors
| HUMANIZED Fab fragment-bouganin
| Pre-clinical trials
|-
| Cixutumumab
| Imclone Systems
| IGF-1 receptor
| Solid tumors
| HUMAN
| Clinical trials
|-
| Clenoliximab
| 
| CD4
| Rheumatoid arthritis
| CHIMERIC (primate/human)
| 
|-
| Clivatuzumab tetraxetan yttrium (90 Y)
| Immunomedics Inc.
| MUC1
| Pancreatic cancer
| HUMANIZED
| Phase II Clinical trials
|-
| Conatumumab (AMG-655)
| Amgen
| TNFRSF10B, TRAIL-R2 (CD262)
| Solid tumors
| HUMAN
| Clinical trials
|-
| CR6261
| The Scripps Research Institute, Crucell
| Influenza A hemagglutinin
| Influenza virus infection
| HUMAN
| Preclinical trials
|-
| Dacetuzumab (SGN 40 or huS2C6)
| Seattle Genetics
| CD40
| Non- Hodgkin's lymphoma and hematological malignancies
| HUMANIZED
| Clinical trials
|-
| Daclizumab (Zenapax®)
| Hoffman-La Roche
| CD25 (IL-2 receptor)
| Refractory unstable angina. Allograft rejection
| HUMANIZED
| FDA 1997 EMEA 1999
|-
| Daratumumab
| Genmab
| CD38
| Multiple myeloma
| HUMAN
| Clinical trials
|-
| Denosumab XGEVA (Prolia®)
| XGEVA, Amgen
| RANKL
| Postmenopausal osteoporosis
| HUMAN
| FDA 2010 EMEA 2010
|-
| Detumomab
| ?
| B cell lymphoma
| B cell lymphoma
| MOUSE
| ?
|-
| Ecromeximab (KW2871)
| Kyowa Hakko Kogyo Co., Ludwig Institute for Cancer Research
| GD3 ganglioside
| melanoma
| CHIMERIC (mouse/human)
| Phase I/II Clinical trials
|-
| Eculizumab (Soliris®)
| Alexion Pharmaceuticals
| C5 Complement factor
| paroxysmal nocturnal hemoglobinuria
| HUMANIZED
| FDA 2007 EMEA 2007
|-
| Edobacomab (E5, XMMEN-0E5)
| Pfizer
| Endotoxin
| Sepsis
| MOUSE
| Clinical trials
|-
| Edrecolomab (Panorex®)
| Imaging Sciences L1c
| EpCAM (17-1A)
| Colorectal cancers
| CHIMERIC
| German approval 1995
|-
| Efalizumab (Raptiva®)
| Genentech Inc./ Roche
| CDlla
| Psoriais
| HUMANIZED
| FDA 2003. Recommended suspension. Withdrawn from market 2009
|-
| Efungumab (Mycograb®)
| NeuTec Pharma (Novartis)
| Fungal HSP90
| Candida infection
| HUMAN single chain variable fragment (scFv)
| Discontinued the development on 2010
|-
| Elotuzumab (HuLuc63)
| PDL BioPharma Bristol Myers
| SLAMf7(CD319)
| Multiple myeloma
| HUMANIZED
| Clinical trials
|-
| Elsilimomab (B-E8)
| ?
| IL-6
| Lymphoma/Myeloma
| MOUSE
| preliminary Clinical trials
|-
| Enlimomab pegol
| Boehringer Ingelheim Pharmaceuticals
| ICAM-1 (CD54)
| Immunomodulator, renal transplant rejection
| MOUSE
| Clinical trials
|-
| Epitumomab cituxetan 90Y
| ?
| Episialin
| Several type of cancers. Epithelial Ovarian cancers
| MOUSE- 90Y
| Phase II
|-
| Epratuzumab
| UCB and Immunomedics
| CD22
| Autoinmune disorders such as lupus, Cancer
| HUMANIZED
| Clinical trials
|-
| Erlizumab (rhuMAbCD18)
| Genentech/Roche
| CD18
| Heart attack, stroke, traumatic shock
| HUMANIZED F(ab')2fragment
| Dropped
|-
| Ertumaxomab (Rexomun®)
| Fresenius Biotech GmbH / TRION Pharma
| HER2/neu, CD3
| Breast cancer
| RAT/MOUSE HYBRID trifucntional antibody
| Phase II Clinical trials
|-
| Etaracizumab o Etaratuzumab MEDI-522 (Abegrin® or Vitaxin)
| Medlmmime, Inc.
| Integrin αv β3
| Several type of cancers
| HUMANIZED
| Clinical trials
|-
| Exbivirumab
| ?
| Hepatitis B surface antigen
| Hepatitis B infections
| HUMAN
| Preclinical
|-
| Fanolesomab (NeutroSpec™)
| Palatin Technologies
| CD15
| Apendicitis
| MOUSE IgM-99mTc-
| FDA 2004 Suspended in 2005
|-
| Faralimomab
| ?
| Interferon receptor
| Immunomodulator
| MOUSE
| ?
|-
| Farletuzumab (MORAb-003)
| Morphotek
| FR-α
| Ovarian cancer
| HUMANIZED
| Phase III Clinical trials
|-
| Felvizumab (SB 209763)
| Centocor Inc. / GlaxoSmithKline
| Respiratory syncytial virus
| Infection by RSV
| HUMANIZED
| Phase III Clinical trials
|-
| Fezakinumab (ILV-094)
| Wyeth - Pfizer
| IL-22
| Rheumatoid arthritis, psoriasis
| HUMAN
| Phase II Clinical trials
|-
| Figitumumab (CP-751871)
| Pfizer
| IGF-1 receptor
| Various types of cancers
| HUMAN
| Clinical trials
|-
| Fontolizumab (HuZAF-™)
| Novartis Pharmaceuticals Corp. / PDL (Protein Design Labs) BioPharma
| Interferon γ
| Auto-immune diseases like Crohn's disease
| HUMANIZED
| Rheumatoid Arthritis dropped, Phase II Clinical trials
|-
| Foravirumab (CR4098)
| Crucell
| Rabies virus glycoprotein
| Infection by rabies virus
| HUMAN
| Phase II Clinical trials
|-
| Fresolimumab
| Genzyme
| TGF β
| Pulmonar fibrosis/cancer
| HUMAN
| Clinical trials 2009
|-
| Galiximab (IDEC-114)
| Biogen Idee
| CD80
| B cell lymphoma, Non-Hodgkin's lymphoma, Psoriasis
| CHIMERIC (primate/human)
| Phase I/II Clinical trials
|-
| Gantenerumab (R1450)
| F. Hoffmann-La Roche Ltd.
| β amyloid
| Alzheimer's disease
| HUMAN
| Phase I Clinical trials
|-
| Gavilimomab (ABX-CBL)
| Abgenix
| CD 147
| Graft versus host disease
| MOUSE
| Phase II/III Clinical trials
|-
| Gemtuzumab ozogamicin (Mylotarg®,CMA-676)
| Wyeth → Pfizer
| CD33
| Relapsed acute myeloid leukaemia
| HUMANIZED-Calicheamicin
| FDA 2000 Suspended in US on 2010
|-
| Girentuximab (Rencarex®cG250, WX-G250)
| Wilex AG, Ludwig Institute for Cancer Research
| Carbonic anhydrase 9 (CA-LX, MN, G250)
| Renal carcinoma
| CHIMERIC
| Phase III Clinical trials
|-
| Girentuximab (Redectane®, 124I_cG250, 1241 WX-G250)
| Wilex AG, Ludwig Institute for Cancer Research
| Carbonic anhydrase 9 (CA-IX, MN, G250)
| Renal mass, kidney tumors
| CHIMERIC
| Phase III Clinical trials
|-
| Glembatumumab vedotin(CR011,CDX-011)
| Celldex Therapeutics, Inc.
| GPNMB (transmembrane glycoprotein NMB)
| Cancer cells expresing NMB: melanoma, breast cancer
| HUMAN- Auristatin
| Phase II Clinical trials
|-
| Golimumab (Simponi®)
| J&J
| TNFα
| Rheumatoid arthritis, psoriatic arthritis and ankylosing spondulitis
| HUMAN
| FDA 2009 EMEA 2009
|-
| Gomiliximab
| IDEC Pharmaceuticals Corporation
| CD23
| Allergic asthma
| CHIMERIC (primate/human)
| withdrawn
|-
| Ibalizumab (TMB-355)
| Tanox; TaiMed Biologies
| CD4
| HIV entry inhibitor
| HUMANIZED
| Clinical trials
|-
| Ibritumomab tiuxetan (Zevalin®)
| Biogen IDEC Pharmaceuticals Corp.
| CD20
| Non-Hodgkin lymphoma
| MOUSE Ig- 90Y
| FDA 2002 EMEA 2004
|-
| Igovomab (Indimacis-125®)
| CIS Bio international
| MUC16CA-125
| Ovarian cancer
| MOUSE conjugated to 111In
| FDA 1996, EC withdrawal 1999
|-
| Imciromab-Pentetate (Myoscint™)
| Centocor
| Heart myosin
| Detection of heart disease
| MOUSE conjugated to 111In
| FDA Orphan product 1989; Withdrawn in 1993
|-
| Infliximab (Remicade®)
| Centocor (J&J)
| TNFα
| Psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis.
| CHIMERIC (mouse/human)
| FDA 1998 /EMEA 1999
|-
| Inolimomab
| OPI (Orphan Pharma International)
| IL2RA, CD25
| Graft-veraMi-host disease
| MOUSE
| Phase II/III Clinical trials
|-
| Inotuzumab ozogamicin (CMC-544)
| Wyeth - Pfizer
| CD22
| Diffuse large B cell lymphoma, Non-Hodgkin lymphoma
| HUMANIZED -Calicheamicin
| Phase II Clinical trials
|-
| Ipilimumab (MDX-101) (Yervoy™)
| Bristol-Myers Squibb.
| CD 152 (CTLA-4)
| Activator of the immune system: late stage melanoma and other type of tumors
| HUMAN
| FDA 2011
|-
| Iratumumab (MDX-060)
| Medarex, Inc.- Bristol-Myers Squibb
| CD30
| CD30-positive lymphoma including Hodgkin's disease
| HUMAN
| Phase II Clinical trials
|-
| Keliximab(IDECCE9.1/SB-210396)
| Biogen IDEC Pharmaceuticals, SKB
| CD4
| Immunosuppressor. Severe chronicAsthma, Rheumatoid arthritis
| CHIMERIC (primate/human)
| Phase III Clinical trials suspended
|-
| Labetuzumab (hMN14, CEACIDE™)
| Immunomedics, Inc
| CEA
| Colorectal tumor
| HUMANIZED
| Phase I/II Clinical trials
|-
| Lebrikizumab (MILR1444A)
| Roche-Genentech
| IL-13
| Asthma
| HUMANIZED
| Phase II Clinical trials
|-
| Lemalesomab
| ?
| NCA-90 (granulocyte antigen)
| Diagnosis of inflammatory lesions
| MOUSE
| ?
|-
| Lerdelimumab (CAT-152)
| Cambridge Antibody Technology
| TGF β
| Immunosuppresor. Glaucoma
| HUMAN
| Phase III Clinical trials
|-
| Lexatumumab (ETR2-ST01)
| HGS; Cambridge Antibody Technology
| TRAIL-R2 (AP02)
| Tumors
| HUMAN
| Clinical trials
|-
| Libivirumab
| ?
| Hepatitis B surface antigen
| Hepatitis B infection
| HUMAN
| Preclinical
|-
| Lintuzumab
| Seattle Genetics
| CD33
| acute myeloid leukemia
| HUMANIZED
| Clinical trials
|-
| Lorvotuzumab mertansine IMGN901
| ImmunoGen, Inc
| CD56
| Small cell lung cancer, ovarian cancer
| HUMANIZED -mertansine
| Orphan drug; clinical trials
|-
| Lucatumumab
| Novartis Pharmaceuticals Corp
| CD40
| Cancer like multiple myeloma, non-Hodgkin's or Hodgkin's lymphoma
| HUMAN
| Clinical trials
|-
| Lumiliximab(IDEC-152,P5E8)
| Biogen IDEC Pharmaceutical
| CD23
| Chronic lymphocytic leukaemia, Allergic asthma
| CHIMERIC (primate/human)
| Phase I/II Clinical trials
|-
| Mapatumumab
| Cambridge Antibody Technology and Human Genome Sciences, Inc.
| TRAIL-receptor (death receptor 4
| Several tumors
| HUMAN
| Clinical trials
|-
| Maslimomab
| ?
| T cell receptor
| Immunosuppresor
| MOUSE
| ?
|-
| Matuzumab (EMD 72000)
| Merck Serono; Takeda Pharmaceutical,
| EGFR
| Several tumors
| HUMANIZED
| Dropped
|-
| Mepolizumab
| GlaxoSmithKline
| IL-5
| Hypereosinophilic syndrome
| HUMANIZED
| Clinical trials
|-
| Metelimumab (CAT-192)
| Cambridge Antibody Technology
| TGF β1
| Scleroderma
| HUMAN
| Dropped
|-
| Milatuzumab
| Immimomedics, Inc
| CD74
| Multiple myeloma
| HUMANIZED-doxorubicin
| Clinical trials
|-
| Minretumomab
| ?
| TAG-72
| Cancer
| MOUSE
| ?
|-
| Mitumomab (BEC2)
| ImClone Systems Inc./ Memorial Sloan-Kettering Cancer Center/Merck KgaA
| GD3 ganglioside
| Melanoma and Small cell lung carcinoma
| MOUSE
| Phase III Clinical trials
|-
| Morolimumab
| ?
| Rhesus factor
| Immunosuppresor
| HUMAN
| ?
|-
| Motavizumab (Numax)
| Medlmmune
| RSV glycoprotein F
| Prevention of respiratory syncitial inf.
| HUMANIZED
| FDA withdrawn 2010
|-
| Muromonab-CD3. (Orthoclone OKT3™)
| Ortho Biotech, Inc. (subsidiary of J&J) Janssen-Cilag
| CD3
| Prevention of organ transplant rejection
| MOUSE
| FDA 1986 EMEA 1987
|-
| Nacolomab tafenatox
| ?
| C242
| Colorectal tumor
| MOUSE-enterotoxin A from Staphylococcus aureus
| ?
|-
| Naptumomab estafenatox (ABR-217620, ANYARA, TTS CD3)
| Active Biotech AB
| TPBG (trophoblast glycoprotein, 5T4)
| Several tumors
| MOUSE Fab fragment-enterotoxin E from Staphylococcus aureus
| Clinical trials
|-
| Natalizumab (Tysabri®)
| Biogen Idee and Elan Corp.
| Integrin α4 subunit ofa4β1
| Multiple Sclerosis, Chron's disease
| HUMANIZED
| FDA 2004/ withdrawn/ back on2006/ EMEA only for restricted cases
|-
| Nebacumab (centoxin, HA-1A. septomonab)
| Centocor
| Endotoxin
| Sepsis
| HUMAN
| Withdrawn in 1993
|-
| Necitumumab (IMC-11F8)
| ImClone Systems Inc.
| EGFR
| Several tumors
| HUMAN
| Clinical trials
|-
| Nerelimomab
| ?
| TNFα
| TNF inhibitor
| MOUSE
| ?
|-
| Nimotuzumab (BIOMab EGFR®) (TheraCIM) (TheraLoc) (CIMAher)
| CIM, Cuba YM Biosciences, Out-licensed to other companies Daiichi Sankyo, Inc (ONLY JAPAN)
| EGFR
| Squamous cell carcinoma and glioma
| HUMANIZED
| Orphan drug FDA, EMEA 2004, Several countries 2005 China; 2006 India.
|-
| Nofetumomab merpentan (Verluma®)
| Boehringer Ingelheim Pharma KG
| Glycoprotein 40 kD
| Detection of tumors
| MOUSE Fab IgG2b-merpentan-99mTc
| FDA 1996
|-
| Ocrelizumab
| Hoffman-La Roche Inc.
| CD20
| Immunosuppresive drug
| HUMANIZED
| Clinical trials
|-
| Odulimomab. (afolimomab. ANTILFA®)
| Pasteur-Merieux
| integrin α L subunit -CDlla
| Allograft Transplant rejection
| MOUSE
| Phase III, not renewed
|-
| Ofatumumab (Arzerra HuMax-CD20®)
| Genmab
| CD20
| Chronic lymphocytic leukemia
| HUMAN
| FDA 2009 EMEA 2010
|-
| Olaratumab (IMC-3G3)
| Imclone
| PDGF-Rα
| Solid tumors
| HUMAN
| Phase I Clinical trials
|-
| Omalizumab (Xolair®)
| Genentech Inc./ Roche/ Tanox, Inc., Novartis Pharmaceuticals
| IgE
| Severe asthma.
| HUMANIZED
| FDA 2003 EMEA 2005
|-
| Oportuzumab monatox. (PROXINIUM™ VICINIUM™)
| Viventia Biotechnologies Inc.
| EpCAM, and others
| Several tumors
| HUMANIZED (sc Fv)- Pseudomonas aeruginosa exotoxin A
| Phase II/III Clinical trials
|-
| Oregovomab (OVAREX®)
| AltaRex Corp
| MUC16, CA-125
| Ovarian tumors
| MOUSE
| Phase II Clinical trials
|-
| Otelixizumab TRX4
| Tolerx, Inc. AND GlaxoSmithKline. Manufact. by Abbott Laboratories
| CD3ε
| Type 1 diabetes and other autoimmune diseases
| CHIMERIC/HUMANIZED
| Clinical trials. Orfan drug status FDA
|-
| Pagibaximab
| Biosynexus, Glaxo Smith Kline
| Staphylococcal lipoteichoic acid
| Prevention of sepsis by staphylococcus
| CHIMERIC (mouse/human)
| Orphan drug status EMEA 2010
|-
| Palivizumab (Synagis™)
| Medimmune Inc.
| An epitope of the RSV F protein
| Respiratory syncitial virus infection
| HUMANIZED
| FDA 1998 EMEA 1999
|-
| Panitumumab (ABX-EGF) (Vectibix™)
| Amgen/Abgenix
| Epidermal growth factor receptor (EGFR)
| Metastatic colorectal carcinoma
| HUMAN
| FDA 2006 EMEA 2007
|-
| Panobacumab (o Aerumab 11) (KBPA-101)
| Kenta Biotech Ltd
| Pseudomona aeruginosa serotype ATS 01l
| Infection by pseudomona
| HUMAN
| Phase I/II Clinical trials
|-
| Pascolizumab
| Centocor Inc. / GlaxoSmithKline
| IL-4
| Allergy, Asthma
| HUMANIZED
| Phase II Clinical trials
|-
| Pemtumomab (Theragyn)
| Antisoma pic Abbot Laboratories
| MUC1
| Ovarian and peritoneal cancer
| MOUSE
| Clinical trials; orphan drug status in FDA and EMEA
|-
| Pertuzumab (Omnitarg™)
| Genentech
| HER2
| Tumors
| HUMANIZED
| Clinical trials
|-
| Pexelizumab
| Procter & Gamble (P&G) Alexion Pharmaceuticals
| C5 Complement component
| Reduce side effects of coronary artery bypass grafting and angioplasty
| HUMANIZED
| Disappointing results on phase III.
|-
| Pintumomab technetium -99mTc
| ?
| Adenocarcinoma antigen
| Imaging of adenocarcinoma
| MOUSE-99mTc
| ?
|-
| Priliximab
| Centocor
| CD4
| Crohn's disease and multiple sclerosis
| CHIMERIC (mouse/human)
| pending
|-
| Pritumumab
| Nascent Biologies, Inc.
| Vimentin
| Brain cancer
| HUMAN
| Clinical trials
|-
| Pro 140
| Progenies Pharmaceuticals
| CCR5
| HIV infection
| HUMANIZED
| Clinical trials/ fast track approval
|-
| Rafivirumab (CR57)
| Crucell
| Rabies virus glycoprotein
| Rabies profilaxis
| HUMAN
| Phase II Clinical trials
|-
| Ramucirumab (IMC-1121B)
| Pfizer/ImClone Systems Inc
| VEGFR-2
| Several tumors
| HUMAN
| Clinical trials.
|-
| Ranibizumab (Lucentis®)
| Genentech Inc. (Roche) / Novartis
| Vascular endothelial growth factor A (VEGF-A)
| Wet Macular degeneration
| HUMANIZED Fab
| FDA 2006 EMEA 2007
|-
| Raxibacumab (ABthrax)
| Human Genome Sciences
| Protective antigen of anthrax toxin
| Antrax toxin
| HUMAN
| Phase III Clinical trials
|-
| Regavirumab
| Teijin
| Cytomegalovirus glycoprotein B
| Cytomegalovirus infection
| HUMAN
| Phase I Clinical trials
|-
| Reslizumab
| Ception Therapeutics, Inc
| IL-5
| Eosinophil-meditated inflammations
| HUMANIZED (from rat)
| Phase II Clinical trials
|-
| Rituximab (Rituxan®) (MabThera®)
| Roche / Biogen Idee
| CD20
| Non-Hodgkin lymphomas, rheumatoid arthritis
| CHIMERIC
| FDA 1997 EMEA 1998
|-
| Robatumumab (SCH 717454)
| Schering-Plough.
| CD221
| Colon sarcoma, Blood cancers
| HUMAN
| Preclinical and Phase II Clinical trials
|-
| Rontalizumab
| Genentech Inc.
| IFNα
| Systemic lupus erythematosus
| HUMANIZED
| Clinical trials.
|-
| Rovelizumab (LeukArrest, Hu23FG2)
| Icos
| CD11,CD18
| Immunosuppresive drug
| HUMANIZED
| FDA 1998, dropped 2000
|-
| Ruplizumab (Antova™)
| Biogen Idee Ma Inc.
| CD154
| Rheumatic diseases
| HUMANIZED
| FSA fast tracked
|-
| Satumomab pendetide (OncoScint CR103™)
| Cytogen Corp. and Cetus Corp, Lonza Biologies
| TAG-72
| Ovarian and Colorectal Cancer diagnosis
| MOUSE-pentetide- 11lIn
| Withdrawn
|-
| Sevirumab (MSL-109) (Protovir™)
| Novartis Pharmaceuticals Corp. / PDL (Protein Design Labs) BioPharma
| CMV
| Cytomegalovirus infection in AIDS patients
| HUMAN
| Phase III
|-
| Sibrotuzumab
| ?
| FAP
| Tumors
| HUMANIZED
| 
|-
| Siltuximab
| Centocor Inc.
| IL-6
| Multiple myeloma and other Tumors
| CHIMERIC (mouse/human)
| Phase II Clinical trials
|-
| Siplizumab (MEDI-507)
| BioTransplant, Medlmmune Inc.
| CD2
| Psoriasis and in the prevention of graft-verms - host disease, and Acute kidney transplant rejection
| HUMANIZED (from rat)
| Phase II Clinical trials
|-
| Solanezumab
| Eli Lilly
| βamyloid
| Alzheimer's disease
| HUMANIZED
| Phase II Clinical trials
|-
| Stamulumab (MYO-029)
| Cambridge Antibody Technology, Wyeth Pharmaceuticals
| Myostatin
| Muscular distrophy
| HUMAN
| Phase I/II Clinical trials
|-
| Sulesomab-Technetium (Leukoscan®)
| Immunomedics Inc, Nycomed GmbH
| NCA-90 (granulocyte cell antigen
| Detection of inflammation, diagnosing osteomyelitis
| MOUSE- 99mTc
| marketed in European Union
|-
| Tacatuzumab tetraxetan-yttrium (90Y) (AFP-Cide)
| Immunomedics Inc.
| α fetoprotein (AFP)
| Cancers
| HUMANIZED-tetraxetan-90y
| withdrawn
|-
| Tadocizumab (C4Gl,YM-337)
| Yamanochi Pharma America, PDL (Protein Design Labs) BioPharma
| Integrin αIIbβ3
| Percutaneous coronary interventions
| HUMANIZED Fab
| Phase II Clinical trials
|-
| Talizumab (TNX-901)
| Tanox, Novartis
| Fc region of IgE
| Allergy reactions
| HUMANIZED
| withdrawn
|-
| Tanezumab (RN624)
| Pfizer
| Nerve growth factor (NGF)
| Pain treatment
| HUMANIZED
| Clinical trials
|-
| Taplitumomab paptox
| ?
| CD19
| Tumors
| MOUSE- conjugated with antiviral protein PAP from Phytolacca americana
| ?
|-
| Tefibazumab (Aurexis®)
| Inhibitex
| Clumping factor A
| Severe infectious with Staphylococcus a.
| HUMANIZED
| Clinical trials
|-
| Telimomab aritox
| ?
| 
| Immunosuppresive drug
| MOUSE (Fab fragment)-ricin protein
| 1991, phase I, discontinued
|-
| Tenatumomab
| Sigma-Tau
| Tenascin C
| Cancer
| MOUSE
| ?
|-
| Teneliximab
| ?
| CD40
| Immunosuppresive drug
| CHIMERIC (mouse/human)
| ?
|-
| Teplizumab MGA031
| Eli Lilly
| CD3
| Diabetes mellitus type 1
| HUMANIZED
| Phase III disappointed
|-
| TGN1412 (CD28-superMAB)
| TeGenero Immuno Therapeutics
| CD28
| B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis,
| HUMANIZED
| Catastrophic systemic organ failure 2006 on phase I
|-
| Tigatuzumab (CS-1008)
| Daiichi Sankyo, Inc
| TRAIL-R2 OrDR5
| Several tumors (colorectal, pancreas, ovary)
| HUMANIZED
| phase II Clinical trials
|-
| TNX-650
| Tanox
| IL-13
| Refractory Hodgkin's lymphoma
| HUMANIZED
| Clinical trials
|-
| Tocilizumab o atlizumab (Actemra®)
| Hoffman-la Roche; Chugai Pharmaceuticals.
| IL-6 receptor
| Rheumatoid arthritis
| HUMANIZED
| EMEA 2009 FDA 2010
|-
| Toralizumab (IDEC 131)
| IDEC Pharmaceuticals Corporation
| CD154 (CD40 ligand)
| Immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis)
| HUMANIZED
| Trials halted on Phase II
|-
| Tositumomab (Bexxar®)
| Corixa Corp and GlaxoSmithKline
| CD20
| Non-Hodgkin follicular lymphoma
| Mouse Ig-131I
| FDA 2003
|-
| Trastuzumab (Herceptin®)
| Genentech Inc. (ROCHE)
| ErbB2 (HER2/neu)
| Breast cancer
| HUMANIZED
| FDA 1998 EMEA 2000
|-
| Tremelimumab o Ticilimumab (CP-675,206)
| Pfizer
| CD 152 (CTLA-4)
| Melanoma/small cell lung cancer/prostate cancer
| HUMAN
| Clinical trials
|-
| Tucotuzumab celmoleukin
| EMD pharmaceuticals
| EpCAM
| Several tumors
| HUMANIZED- celmoleukin (IL-2)
| Clinical trials
|-
| Tuvirumab
| PDL (Protein Design Labs) BioPharma
| Hepatitis B virus
| Chronic hepatitis B
| HUMAN
| Phase I clinical trials in 2001
|-
| Urtoxazumab
| TMA-15 TEIJIN
| E coli Shiga like toxin II B (STEC 0-157 infection)
| Diarrhoea by Escherichia coli (serotype 0121)
| HUMANIZED
| Phase II Clinical trials
|-
| Ustekinumab (Stelara®)
| J&J
| P40fromIL-12 and IL-23
| Psoriasis, multiple sclerosis
| HUMAN
| FDA 2009 EMEA 2008
|-
| Vapaliximab
| (HUVAP) Biotie Therapies (VAP-1 fully human) Turku-Finland
| Vascular adhesion protein (VAP-1)
| Inflammation
| CHIMERIC (mouse/human)
| Phase I (2002)
|-
| Vedolizumab
| Millennium Pharmaceuticals
| Integrin α4β7
| Ulcerative colitis and Crohn's disease
| HUMANIZED
| Clinical trials
|-
| Veltuzumab
| Immunomedics, Inc
| CD20
| Non-Hodking's lymphoma
| HUMANIZED
| Clinical trials
|-
| Vepalimomab (vepalimomabum)
| Biotie Therapies (VAP-1 fully human)
| Vascular adhesion protein (VAP-1)
| Inflammation
| MOUSE HUMAN
| Phase 2 enabling work underway.(Scifinder)Immunoglobulin M, anti-(human vascular adhesion protein VAP-1)(mouse monoclonal 1B2μchain) disulfide with mouse monoclonal 1B2 light chain, dimer
|-
| Visilizumab (Nubion)
| PDL BioPharma Inc
| CD3
| Multiple myeloma and diabetes mellitus type 1
| HUMANIZED
| Clinical trials
|-
| Volociximab
| PDL BioPharma and Biogen Idee
| Integrin α5β1
| Solid tumors
| CHIMERIC(mouse/human)
| Clinical trials
|-
| 99mTc -Votumumab (HumaSPECT®)
| KS Biomedix Ltd, Non commercialized
| CTAA16.88 cytokeratin polypeptides
| Detection of colorectal tumor. Diagnostic imaging
| HUMAN- 99mTc
| EC withdrawal
|-
| Zalutumumab (HuMax-EGFR)
| GenMab
| EGFR
| Squamous cell carcinoma resistant to chemotherapy
| HUMAN- BSC
| Clinical trials
|-
| Zanolimumab (HuMax-CD4)
| GenMab
| CD4
| Rheumatoid arthritis/psoriasis/melanoma/T cell lymphoma
| HUMAN
| Clinical trials
|-
| Zolimomab aritox
| XOMA Corp CD5 Plus; H65-RTA; Orthozyme CD5plus; XZ-CD5; XomaZyme-H65
| CD5
| Systemic lupus erythematosus / graft versus host disease
| MOUSE-ricin protein
| the studies failed to show positive effects(Immunotoxin)
|}
[[Category:Antibodies]]